VivoSim Labs Inc
organovo.comWhat Do They Do?
Provides liver and intestinal drug-testing services using human tissue models to pharmaceutical and biotechnology companies.
10-K for FY2026, filed Jul 14, 2026
How Do They Make Money?
License partners pay upfront fees and royalties tied to net product sales; cell-based products were paid for upon delivery.
10-K for FY2026, filed Jul 14, 2026
-
10-K for FY2026, filed Jul 14, 2026
FY2026 revenue by product or service ↗
$131K
-
10-K for FY2026, filed Jul 14, 2026
$131K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Royalty
Licensed
10-K for FY2026, filed Jul 14, 2026 |
100% |
Royalty, FY2026
$131K Sources
|
Licensed |
|
Product
Sold outright
|
0.0% |
Product, FY2026
$0 Sources
|
Sold outright |
Who Are Their Customers?
The company offers liver and intestinal toxicology testing and research to pharmaceutical and biotechnology companies developing drug candidates.
10-K for FY2026, filed Jul 14, 2026We are now offering liver toxicology predictive screening and research services as well as working on predicting and studying the…View ↗
Do Revenues Turn Into Profits?
No. It lost $13.8M in FY2026.
10-K for FY2026, filed Jul 14, 2026
−$11.5MView ↗
10-K for FY2026, filed Jul 14, 2026
−$13.8MView ↗
10-K for FY2026, filed Jul 14, 2026
−$10.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Aug 12, 2026
−$1.3MView ↗
- ▼ −53% (Loss)
- vs −$2.8M in Q1 FY2026
10-Q for Q1 FY2027, filed Aug 12, 2026
Open tableView ↗
-
Aug 21, 2026
Nasdaq notified the company it fell below the minimum bid-price requirement
It has until February 16, 2027 to regain compliance; trading was not immediately affected.
Sources
8-K, filed Aug 21, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until…View ↗
-
Aug 6, 2026
Company reiterated guidance for 500%+ revenue growth in Fiscal Year 2027
The update followed a $5.0 million milestone payment and release of $1.0 million from escrow.
Sources
8-K, filed Aug 6, 2026
Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on July 14…View ↗
-
Jul 24, 2026
Nasdaq notified the company it failed an equity-listing requirement
The company said its stockholders’ equity was above $2.5 million after transactions and planned to submit a compliance plan.
Sources
8-K, filed Jul 24, 2026
Although the Company intends to submit to Nasdaq, within the requisite time period, a plan to regain compliance with Rule 5550(b)(1), as of…View ↗
Shrinking. Revenue fell 91% in 4 years, from $1.5M in FY2022 to $131K in FY2026, about 46% a year.
From drug development to testing services
The older report centered on building disease models to identify targets and develop internal drugs, especially for inflammatory bowel disease. The latest report centers on liver and intestinal toxicology testing for outside drug developers, after the company sold its FXR program.
10-K for FY2023, filed Jul 14, 2023 10-K for FY2026, filed Jul 14, 2026VivoSim Labs, Inc. ("VivoSim," “we,” “us,” “our,” the “Company” and “our Company”), is a pharmaceutical and biotechnology services company…View ↗
Prior to March 2025, we were a clinical stage biotechnology company that was focused on developing FXR314 in inflammatory bowel disease…View ↗
In March 2025, we sold our FXR program for $10.0 million, with $9.0 million paid at closing and $1.0 million held in escrow for a period of…View ↗
We are now offering liver toxicology predictive screening and research services as well as working on predicting and studying the…View ↗
Who Do They Compete With?
Competes with BICO Group
10-K for FY2026, filed Jul 14, 2026Our U.S. Patent Nos. 9,855,369 and 9,149,952, which relate to our bioprinter technology, were the subject of inter partes review…View ↗
Loading...
